What is Laquinimod?
Laquinimod is a drug with immunomodulatory effects that changes the function of the immune system in patients. Since 2011, this medicine has been experimental and available only through clinical evaluation. This medicine has an application in the treatment of autoimmune disease, where the patient's body continues to attack and causes damage to its own tissues. Such diseases are stubborn and demanding for treatment, so new therapeutic agents are very attractive. Clinical studies with laquinimod have shown the most promising in the treatment of multiple sclerosis, where it seems to slow plaque formation and can reduce the intensity of relapses in patients with relapse-resigning multiple sclerosis. Laquinimod could maintain patients with this degenerative nerve disease with comforts with neurological diseases as a maintenance medicine. The mechanism of action is not fully understood as to how the examinations are, where scientists still learn more about how they work and work to see if they are commercially developing for the treatment of the disease.
Information on the side effects of drugs in clinical trials usually does not choose. The drug manufacturer wants to compare side effects for patients on placebo with patients taking the drug and also identify potentially serious and fatal side effects to see if the drug is too dangerous to release. Medicines known to affect the immune system such as laquinimod can cause people to infect more and can lead to problems such as skin rashes, allergic reactions and increased chances of coughing, colds and flu.
people interested in accessing experimental drugs such as laquinimod can look at the database of clinical trials to see if any attempts are open. Open record tests are accepted by patients who correspond to a specific set of parameters. A doctor may have studies that could recommend and can also diskTow about other ongoing clinical trials with the patient. During the registration process, the patient learns more about the risks and benefits of the court proceedings and may use this information to decide whether to move forward with participation.